

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound consisting of the formula X<sub>1</sub>-SEQ ID NO:1-X<sub>2</sub> wherein

X<sub>1</sub> is from zero to twelve amino acids, and

X<sub>2</sub> is from zero to twelve amino acids.

2. (Original) The composition of Claim 1, wherein

X<sub>1</sub> is from zero to six amino acids, and

X<sub>2</sub> is from zero to six amino acids

3. (Original) The composition of claim 1 wherein

X<sub>1</sub> is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

X<sub>2</sub> is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.

4. (Original) The composition of claim 1 wherein the compound has substantial amino acid sequence homology to the amino acid sequence SEQ ID NO:4.

5. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:1.

6. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:9.

7. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:10.

8. Cancelled

9. Cancelled

10. Cancelled

11. Cancelled

12. Cancelled

13. Cancelled

14. Cancelled

15. Cancelled
16. Cancelled
17. Cancelled
18. Cancelled
19. Cancelled
20. Cancelled
21. Cancelled
22. Cancelled
23. Cancelled
24. (Original) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a composition according to claim 1.
25. Cancelled
26. Cancelled
27. Cancelled

28. Cancelled

29. Cancelled

30. Cancelled

31. Cancelled

32. Cancelled

33. Cancelled

34. Cancelled

35. Cancelled

36. Cancelled

37. Cancelled

38. Cancelled

39. Cancelled

40. Cancelled

41. Cancelled

42. Cancelled

43. Cancelled

44. Cancelled

45. Cancelled

46. Cancelled

47. Cancelled

48. Cancelled

49. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 2.

50. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 3.

51. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 4.

52. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 5.

53. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 6.

54. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 7.

55. (Previously presented) A method for inhibiting angiogenesis comprising administering to a mammal an effective amount of a compound of the formula X<sub>1</sub>-SEQ ID NO:1-X<sub>2</sub> wherein

X<sub>1</sub> is from zero to twelve amino acids, and

X<sub>2</sub> is from zero to twelve amino acids.

56. (Previously presented) A method of inhibiting angiogenesis according to claim 1 wherein

X<sub>1</sub> is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

X<sub>2</sub> is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.